Tag Archives: regain

‘New GSK’ shows strength amid investor pressure, but Shingrix still needs to regain its footing

As activist investor Elliott Management turns up the heat on GlaxoSmithKline, CEO Emma Walmsley’s new vision for the company is showing strength. But while Glaxo’s vaccines business does gangbusters overall, its crown jewel Shingrix has yet to hit its stride after the pandemic knocked it off its course. GSK’s shingles vaccine reeled in £295 million… Read More »